Former Chairman Gifford Upjohn, MD, dies Dec. 20 at the age of 89. Upjohn, a grandson of company founder Henry Uriah Upjohn, served as chairman from 1962 to his retirement in 1969; he remained on the board of directors until 1978. During his tenure as an executive for the company, Upjohn testified before Sen. Kefauver in 1959 and 1960 about drug industry pricing; the Kefauver hearings ultimately led to legislation directing FDA to review drugs for efficacy as well as safety prior to approval. Upjohn served as president of the National Vitamin Foundation from 1948-1952
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth